Go Pro
→ New Form of AI Could Ignite the ‘Great Wealth Rotation’ (From Chaikin Analytics) (Ad)tc pixel Free TRVI Stock Alerts

Trevi Therapeutics (TRVI) Financials

Trevi Therapeutics logo
$14.95 -0.26 (-1.71%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$14.96 +0.01 (+0.07%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Trevi Therapeutics

Annual Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -27 -33 -34 -29 -29 -48 -43
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48 -43
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48 -43
Total Pre-Tax Income 		-21 -26 -33 -34 -29 -29 -48 -43
Total Operating Income		 -18 -27 -32 -32 -30 -34 -52 -49
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 27 32 32 30 34 52 49
Selling, General & Admin Expense		 4.34 7.31 10 9.49 10 10 12 16
Research & Development Expense		 14 19 22 23 20 24 39 33
Total Other Income / (Expense), net		 -2.26 0.58 -0.29 -1.49 0.72 4.83 3.58 6.51
Interest Expense		 0.17 0.00 0.46 1.20 1.16 0.39 0.00 0.00
Interest & Investment Income		 0.16 0.79 0.18 0.01 1.74 4.75 3.60 6.54
Other Income / (Expense), net		 -2.24 -0.22 -0.01 -0.29 0.14 0.47 -0.02 -0.03
Income Tax Expense		 -0.12 -0.02 -0.02 -0.02 -0.04 -0.03 -0.03 -0.06
Basic Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Weighted Average Basic Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M 134.75M
Diluted Earnings per Share		 ($58.44) ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Weighted Average Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 64.54M 99.03M 101.97M 134.75M
Weighted Average Basic & Diluted Shares Outstanding		 437.61K 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M 128.40M

Quarterly Income Statements for Trevi Therapeutics

This table shows Trevi Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.85 -11 -12 -13 -12 -10 -12 -12 -8.32 -13 -18
Consolidated Net Income / (Loss)		 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13 -18
Net Income / (Loss) Continuing Operations		 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13 -18
Total Pre-Tax Income 		-7.80 -11 -12 -13 -11 -10 -12 -12 -8.33 -13 -18
Total Operating Income		 -8.93 -12 -13 -14 -12 -11 -14 -14 -10 -15 -21
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 8.93 12 13 14 12 11 14 14 10 15 21
Selling, General & Admin Expense		 2.42 3.10 3.27 2.86 2.91 3.66 4.33 3.83 4.03 4.97 5.36
Research & Development Expense		 6.52 8.80 10 11 9.33 7.81 9.39 10 6.19 9.94 15
Total Other Income / (Expense), net		 1.13 1.00 0.93 0.81 0.84 1.12 1.40 2.10 1.89 1.70 2.69
Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Interest & Investment Income		 1.14 1.00 0.94 0.83 0.84 1.13 1.41 2.10 1.90 1.70 2.70
Other Income / (Expense), net		 -0.00 -0.00 -0.01 -0.01 0.00 -0.01 -0.01 -0.00 -0.02 0.00 -0.00
Income Tax Expense		 0.02 -0.01 -0.01 -0.03 0.02 -0.01 -0.02 -0.02 -0.02 -0.02 -0.02
Basic Earnings per Share		 ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09) ($0.11)
Weighted Average Basic Shares Outstanding		 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M 156.60M
Diluted Earnings per Share		 ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09) ($0.11)
Weighted Average Diluted Shares Outstanding		 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M 156.60M
Weighted Average Basic & Diluted Shares Outstanding		 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M 121.78M 128.23M 128.40M 141.98M 142.48M

Annual Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -15 50 -12 -8.17 -24 20 1.70 -15
Net Cash From Operating Activities		 -18 -23 -29 -29 -28 -32 -38 -42
Net Cash From Continuing Operating Activities		 -18 -23 -29 -29 -28 -32 -38 -42
Net Income / (Loss) Continuing Operations		 -21 -26 -33 -34 -29 -29 -48 -43
Consolidated Net Income / (Loss)		 -21 -26 -33 -34 -29 -29 -48 -43
Depreciation Expense		 0.02 0.04 0.05 0.05 0.04 0.12 0.15 0.14
Amortization Expense		 0.06 0.00 0.23 0.60 -0.31 -1.95 -1.37 -1.64
Non-Cash Adjustments To Reconcile Net Income		 2.77 0.97 2.43 2.84 2.47 3.02 4.05 5.66
Changes in Operating Assets and Liabilities, net		 -0.64 1.95 1.06 1.51 -1.23 -3.85 6.83 -3.49
Net Cash From Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22 -94
Net Cash From Continuing Investing Activities		 -0.16 -0.01 -0.03 0.00 -107 59 -22 -94
Purchase of Property, Plant & Equipment		 -0.16 -0.01 -0.03 0.00 -0.16 -0.14 -0.04 -0.01
Purchase of Investments		 - - - 0.00 -126 -9.93 -98 -171
Sale and/or Maturity of Investments		 - - - 0.00 19 69 77 77
Net Cash From Financing Activities		 3.63 73 17 21 111 -7.91 61 121
Net Cash From Continuing Financing Activities		 3.63 73 17 21 111 -7.91 61 121
Repurchase of Common Equity		 -1.53 -1.21 -0.38 -0.38 -0.23 -0.26 0.00 -0.81
Issuance of Common Equity		 0.00 65 0.01 14 105 0.07 0.07 0.12
Other Financing Activities, net		 -0.52 -0.64 3.17 7.51 12 1.69 61 122
Cash Interest Paid		 0.15 0.00 0.18 0.60 0.59 0.33 0.00 0.00

Quarterly Cash Flow Statements for Trevi Therapeutics

This table details how cash moves in and out of Trevi Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 6.43 -19 -0.85 3.09 18 -15 98 -60 -38 0.50 33
Net Cash From Operating Activities		 -6.36 -10 -8.68 -9.56 -9.55 -13 -10 -11 -7.63 -17 -17
Net Cash From Continuing Operating Activities		 -6.36 -10 -8.68 -9.56 -9.55 -13 -9.99 -11 -7.63 -17 -20
Net Income / (Loss) Continuing Operations		 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13 -18
Consolidated Net Income / (Loss)		 -7.82 -11 -12 -13 -11 -10 -12 -12 -8.32 -13 -18
Depreciation Expense		 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03
Amortization Expense		 -0.35 -0.38 -0.34 -0.35 -0.30 -0.40 -0.38 -0.30 -0.56 -0.43 -0.52
Non-Cash Adjustments To Reconcile Net Income		 1.04 0.84 1.24 0.85 1.12 1.32 1.61 1.35 1.49 2.30 1.16
Changes in Operating Assets and Liabilities, net		 0.74 -0.06 2.73 3.15 1.01 -4.10 1.05 -0.17 -0.27 -5.40 -2.52
Net Cash From Investing Activities		 13 -8.09 2.77 7.67 -24 -9.95 -2.61 -51 -31 17 -112
Net Cash From Continuing Investing Activities		 13 -8.09 2.77 7.67 -24 -9.95 -2.61 -51 -31 17 -112
Purchase of Property, Plant & Equipment		 -0.02 - -0.03 - -0.01 0.00 - -0.01 - -0.10 -0.12
Purchase of Investments		 -0.95 -30 -9.96 -13 -45 -28 -17 -72 -54 -8.49 -154
Sale and/or Maturity of Investments		 14 22 13 21 21 18 15 21 24 26 42
Net Cash From Financing Activities		 -0.05 -0.03 5.07 4.98 51 8.71 110 1.63 0.28 0.22 164
Net Cash From Continuing Financing Activities		 -0.05 -0.03 5.07 4.98 51 8.71 110 1.63 0.28 0.22 164
Repurchase of Common Equity		 -0.06 0.00 - - - -0.22 -0.37 -0.22 - 0.00 -0.45
Other Financing Activities, net		 -0.03 -0.03 5.03 4.98 51 8.93 2.55 1.85 108 0.22 1.72

Annual Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 11 60 47 38 123 89 111 193
Total Current Assets		 8.82 60 46 38 123 88 109 192
Cash & Equivalents		 7.20 57 45 37 13 32 34 19
Short-Term Investments		 - - - 0.00 108 51 74 169
Prepaid Expenses		 1.44 1.68 1.00 0.89 0.80 3.62 0.94 1.26
Other Current Assets		 0.18 0.56 0.27 0.24 1.31 0.96 0.87 2.13
Plant, Property, & Equipment, net		 0.15 0.12 0.10 0.05 0.17 0.22 0.16 0.18
Total Noncurrent Assets		 1.55 0.33 0.76 0.47 0.23 1.64 1.32 1.61
Noncurrent Note & Lease Receivables		 - - - - 0.00 0.21 0.16 0.00
Other Noncurrent Operating Assets		 1.55 0.33 0.76 0.47 0.23 1.43 1.16 1.61
Total Liabilities & Shareholders' Equity		 11 60 47 38 123 89 111 193
Total Liabilities		 4.28 5.46 20 21 16 6.86 11 10
Total Current Liabilities		 2.68 5.20 5.56 13 13 5.82 11 9.75
Accounts Payable		 0.60 1.60 2.02 2.85 2.86 1.81 3.41 3.91
Accrued Expenses		 2.07 3.50 3.43 3.81 3.52 3.71 6.81 5.53
Other Current Liabilities		 0.00 0.10 0.11 0.23 0.03 0.31 0.29 0.31
Total Noncurrent Liabilities		 1.60 0.26 14 8.68 2.16 1.03 0.75 0.45
Long-Term Debt		 - 0.00 14 8.65 2.15 0.00 - 0.00
Other Noncurrent Operating Liabilities		 1.56 0.00 0.20 0.00 0.00 0.03 0.75 0.45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 55 27 17 107 83 100 183
Total Preferred & Common Equity		 -109 55 27 17 107 83 100 183
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -109 55 27 17 107 83 100 183
Common Stock		 0.00 169 174 198 318 322 387 513
Retained Earnings		 -109 -114 -147 -181 -210 -239 -287 -330
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -0.12 -0.03 0.06 0.15

Quarterly Balance Sheets for Trevi Therapeutics

This table presents Trevi Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 116 101 96 79 74 69 107 208 199 180 331
Total Current Assets		 114 99 94 77 72 67 106 207 198 176 326
Cash & Equivalents		 12 14 26 14 13 16 19 117 57 19 54
Short-Term Investments		 100 80 63 59 57 49 84 87 138 152 265
Prepaid Expenses		 1.33 2.98 4.04 3.23 1.80 1.18 1.53 1.77 1.38 2.22 4.26
Other Current Assets		 1.61 2.08 1.05 0.72 0.83 0.67 0.83 1.58 2.00 2.12 2.57
Plant, Property, & Equipment, net		 0.25 0.23 0.24 0.20 0.20 0.17 0.28 0.24 0.21 0.27 0.34
Total Noncurrent Assets		 1.76 1.54 1.71 1.59 1.48 1.40 1.11 0.87 0.84 3.22 4.48
Noncurrent Note & Lease Receivables		 0.24 0.23 0.22 0.19 0.18 0.17 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 1.52 1.31 1.49 1.40 1.30 1.23 1.11 0.87 0.84 3.22 4.48
Total Liabilities & Shareholders' Equity		 116 101 96 79 74 69 107 208 199 180 331
Total Liabilities		 14 5.90 6.29 6.23 7.64 9.94 7.55 9.85 9.57 7.48 9.01
Total Current Liabilities		 13 4.71 5.17 5.28 6.75 9.12 6.87 9.24 9.04 7.12 8.74
Accounts Payable		 1.98 1.35 1.26 2.11 1.51 1.61 1.42 2.97 2.71 2.22 3.10
Accrued Expenses		 3.47 3.08 3.63 2.84 4.93 7.21 5.17 5.98 6.04 4.58 5.31
Other Current Liabilities		 0.26 0.28 0.29 0.32 0.31 0.30 0.28 0.29 0.30 0.32 0.33
Total Noncurrent Liabilities		 1.27 1.19 1.11 0.95 0.88 0.82 0.68 0.61 0.53 0.36 0.28
Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.12 0.09 0.06 0.00 0.00 0.00 0.68 0.61 0.53 0.36 0.28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 102 95 90 72 66 59 99 198 190 172 322
Total Preferred & Common Equity		 102 95 90 72 66 59 99 198 190 172 322
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 102 95 90 72 66 59 99 198 190 172 322
Common Stock		 318 319 321 322 329 334 397 508 511 515 683
Retained Earnings		 -216 -224 -231 -250 -262 -276 -297 -310 -321 -343 -361
Accumulated Other Comprehensive Income / (Loss)		 -0.09 -0.25 -0.22 -0.07 -0.08 0.14 0.07 0.02 0.03 -0.19 -0.43

Annual Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - 128,230,134.00
DEI Adjusted Shares Outstanding		 - - - - - - - 128,230,134.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.33
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36 -35
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -28.42% -35.93% -18.84%
Earnings before Interest and Taxes (EBIT)		 -21 -27 -32 -33 -30 -33 -52 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -27 -32 -32 -30 -35 -53 -51
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -17 -22 -21 -22 -28 -28 -37
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.91 -2.51 -3.62 -5.25 -3.90 0.58 -7.23 -5.02
Increase / (Decrease) in Invested Capital		 0.00 -1.60 -1.11 -1.63 1.35 4.48 -7.81 2.96
Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30 $1.43
Tangible Book Value per Share		 ($250.21) $3.06 $1.48 $0.66 $1.79 $1.29 $1.30 $1.43
Total Capital		 6.29 55 41 32 117 84 100 183
Total Debt		 0.05 0.26 14 15 9.15 1.00 0.75 0.00
Total Long-Term Debt		 0.05 0.26 14 8.68 2.15 1.00 0.75 0.00
Net Debt		 -7.16 -57 -31 -22 -111 -82 -107 -188
Capital Expenditures (CapEx)		 0.16 0.01 0.03 0.00 0.16 0.14 0.04 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.05 -2.96 -4.29 -5.76 -4.29 -1.25 -8.70 -6.35
Debt-free Net Working Capital (DFNWC)		 6.15 54 41 31 116 82 99 182
Net Working Capital (NWC)		 6.15 54 41 25 109 82 99 182
Net Nonoperating Expense (NNE)		 7.66 7.40 10 11 8.22 5.32 12 8.23
Net Nonoperating Obligations (NNO)		 -7.16 -57 -31 -22 -111 -82 -107 -188
Total Depreciation and Amortization (D&A)		 0.08 0.04 0.27 0.65 -0.27 -1.82 -1.22 -1.49
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M 134.75M
Adjusted Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) ($0.45) ($0.29) ($0.47) ($0.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.83M 19.91M 30.81M 64.54M 99.03M 101.97M 134.75M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.28) ($1.81) ($1.49) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.74M 18.06M 22.84M 60.05M 68.96M 96.68M 128.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -19 -23 -23 -21 -24 -36 -35
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Trevi Therapeutics

This table displays calculated financial ratios and metrics derived from Trevi Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 128,230,134.00 128,397,271.00 141,979,708.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 128,230,134.00 128,397,271.00 141,979,708.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.06 -0.10 -0.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 -35.80% -53.76% -58.29% -52.25% -35.10% 3.42% -3.55% 1.64% - -29.33% -49.18%
EBIT Growth		 -40.33% -60.95% -61.55% -58.56% -36.97% 3.62% -3.27% 1.28% - -29.91% -49.41%
NOPAT Growth		 -34.19% -57.42% -58.54% -55.74% -37.04% 3.66% -3.26% 1.21% - -30.01% -49.46%
Net Income Growth		 -42.07% -70.32% -72.88% -72.02% -45.95% 5.16% 0.41% 10.87% - -27.58% -44.68%
EPS Growth		 -260.00% -83.33% -71.43% -62.50% -37.50% 18.18% 25.00% 38.46% - 0.00% -22.22%
Operating Cash Flow Growth		 -0.44% -27.69% 12.07% -31.28% -50.18% -28.76% -16.33% -13.86% - -23.83% -72.55%
Free Cash Flow Firm Growth		 -78.57% -7.80% 64.89% 81.88% 92.90% 61.15% -37.28% -336.89% - -287.21% -236.59%
Invested Capital Growth		 114.80% 151.67% -220.58% -418.35% -1,353.21% -920.73% -121.26% 9.97% - 109.05% 148.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 2.28% -32.44% -10.93% -6.06% 13.29% 5.32% -18.93% -0.74% - -42.15% -37.18%
EBIT Q/Q Growth		 -0.51% -33.25% -11.65% -6.05% 13.18% 6.24% -19.63% -1.38% - -45.64% -37.59%
NOPAT Q/Q Growth		 1.24% -33.28% -11.62% -6.01% 13.10% 6.31% -19.63% -1.41% - -45.91% -37.53%
Net Income Q/Q Growth		 -1.60% -39.39% -13.30% -7.21% 13.80% 9.42% -18.97% 4.06% - -58.63% -34.91%
EPS Q/Q Growth		 0.00% -37.50% -9.09% -8.33% 15.38% 18.18% 0.00% 11.11% - -50.00% -22.22%
Operating Cash Flow Q/Q Growth		 12.64% -64.60% 17.04% -10.05% 0.06% -41.12% 25.05% -7.71% - -118.70% -4.43%
Free Cash Flow Firm Q/Q Growth		 17.63% 9.65% 50.02% 51.29% 67.74% -394.62% -76.59% -55.03% - -44.15% -53.50%
Invested Capital Q/Q Growth		 -67.82% -19.76% -626.35% -134.22% -26.68% 47.45% -41.89% 4.69% - 106.86% 666.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 100.23% 99.93% 99.94% 99.77% 100.15% 99.89% 99.83% 99.87% - 99.85% 99.89%
Interest Burden Percent		 87.32% 91.63% 92.97% 94.15% 93.12% 90.20% 89.75% 84.90% - 88.62% 86.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -30.59% -38.57% -48.09% -59.65% -52.59% -55.12% -35.74% -36.87% - -33.59% -19.66%
Cash Return on Invested Capital (CROIC)		 -4,891.01% -6,078.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -11,942.73% -1,886.11%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -30.59% -38.57% -48.09% -59.65% -52.59% -55.12% -35.74% -36.87% - -33.59% -19.66%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -46.40% -58.59% -75.15% 0.00% -47.61% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03 -9.61 -9.74 -7.15 -10 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.62% -2.94% -3.77% -4.43% -3.01% -2.64% -1.98% -1.59% - -2.00% -1.32%
Return On Investment Capital (ROIC_SIMPLE)		 -7.48% - - - -8.54% -8.07% -4.84% -5.13% -3.90% -6.06% -4.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.94 -12 -13 -14 -12 -11 -14 -14 -10 -15 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.25 -12 -14 -14 -12 -12 -14 -14 -11 -15 -21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.04 3.29 3.17 4.11 3.18 6.11 2.80 5.87 - 8.90 8.24
Price to Tangible Book Value (P/TBV)		 1.04 3.29 3.17 4.11 3.18 6.11 2.80 5.87 - 8.90 8.24
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.24 358.62 0.00 0.00 0.00 0.00 0.00 0.00 - 3,953.48 883.56
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -1.02 -1.00 -1.00 -1.03 -1.04 -1.02 -1.03 -1.04 - -1.01 -1.01
Leverage Ratio		 1.12 1.12 1.08 1.11 1.10 1.08 1.07 1.08 - 1.06 1.04
Compound Leverage Factor		 0.98 1.03 1.01 1.04 1.02 0.97 0.96 0.92 - 0.94 0.90
Debt to Total Capital		 1.20% 1.30% 1.32% 1.36% 0.74% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 1.20% 1.30% 1.32% 1.36% 0.74% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 98.80% 98.71% 98.68% 98.64% 99.26% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 -0.03 -0.02 -0.02 -0.02 -0.01 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 2.32 1.82 1.54 1.31 2.03 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 -0.03 -0.02 -0.02 -0.02 -0.01 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 -0.04 -0.04 -0.03 -0.02 -0.02 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 3.45 2.68 2.27 1.92 2.96 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 -0.04 -0.04 -0.03 -0.02 -0.02 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 4.51 19.07 11.98 9.38 13.96 45.21 32.76 68.53 - 121.07 175.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.03 14.55 10.68 7.38 10.41 15.38 22.42 21.93 - 24.75 37.28
Quick Ratio		 14.25 13.80 10.29 7.18 10.24 15.04 22.06 21.56 - 24.14 36.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -9.69 -4.84 -2.36 -0.76 -3.77 -6.65 -10 -10 -15 -22
Operating Cash Flow to CapEx		 -28,904.55% 0.00% -31,010.71% 0.00% -136,428.57% 0.00% 0.00% -90,666.67% - -16,361.76% -14,055.65%
Free Cash Flow to Firm to Interest Expense		 -2,682.03 -9,693.20 -4,844.30 -2,359.90 -761.40 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 -1,589.75 -10,467.00 -8,683.00 -9,556.00 -9,550.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,595.25 -10,467.00 -8,711.00 -9,556.00 -9,557.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.58 0.46 -2.44 -5.71 -7.23 -3.80 -5.39 -5.14 -5.02 0.34 2.64
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.48 1.36 -4.46 -7.50 -7.81 -4.26 -2.96 0.57 2.96 4.14 8.03
Enterprise Value (EV)		 3.60 166 141 178 210 505 353 919 - 1,360 2,329
Market Capitalization		 86 238 210 242 317 608 557 1,114 - 1,532 2,648
Book Value per Share		 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03 $1.95 $1.56 $1.43 $1.34 $2.26
Tangible Book Value per Share		 $1.29 $1.05 $0.94 $0.81 $1.30 $1.03 $1.95 $1.56 $1.43 $1.34 $2.26
Total Capital		 84 73 67 60 100 99 198 190 183 172 322
Total Debt		 1.00 0.95 0.88 0.82 0.75 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.00 0.95 0.88 0.82 0.75 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -82 -72 -69 -65 -107 -103 -204 -195 -188 -172 -319
Capital Expenditures (CapEx)		 0.02 0.00 0.03 0.00 0.01 0.00 0.00 0.01 0.00 0.10 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.25 -1.33 -4.12 -7.28 -8.70 -4.50 -5.90 -5.67 -6.35 -2.78 -1.90
Debt-free Net Working Capital (DFNWC)		 82 71 65 58 99 99 198 189 182 169 317
Net Working Capital (NWC)		 82 71 65 58 99 99 198 189 182 169 317
Net Nonoperating Expense (NNE)		 1.57 2.57 3.05 3.38 2.85 2.31 2.70 2.06 1.16 2.75 3.44
Net Nonoperating Obligations (NNO)		 -82 -72 -69 -65 -107 -103 -204 -195 -188 -172 -319
Total Depreciation and Amortization (D&A)		 -0.32 -0.35 -0.30 -0.32 -0.26 -0.36 -0.35 -0.26 -0.53 -0.40 -0.48
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M 156.60M
Adjusted Diluted Earnings per Share		 ($0.08) ($0.11) ($0.12) ($0.13) ($0.11) ($0.09) ($0.09) ($0.08) ($0.06) ($0.09) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 99.03M 99.52M 101.04M 101.28M 101.97M 117.61M 130.35M 145.10M 134.75M 145.59M 156.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 68.96M 70.44M 72.59M 76.87M 96.68M 101.74M 121.78M 128.23M 128.40M 141.98M 142.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.25 -8.33 -9.30 -9.86 -8.57 -8.03 -9.61 -9.74 -7.15 -10 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,234.00 -11,907.00 -13,294.00 -14,098.00 -12,240.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 -1,563.28 -8,334.20 -9,302.30 -9,860.90 -8,569.40 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2,239.50 -11,907.00 -13,322.00 -14,098.00 -12,247.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -1,568.78 -8,334.20 -9,330.30 -9,860.90 -8,576.40 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 -0.89% -0.72% -0.59% -0.13% 0.00% -0.47% -1.25% -1.76% - -1.29% -1.30%

Financials Breakdown Chart

Key Financial Trends

Trevi Therapeutics (NASDAQ: TRVI) remains a pre-revenue biotechnology company with a strong liquidity position but rising operating expenses and continued losses. The company reported no revenue in each presented quarter, meaning its financial outlook remains dependent on clinical progress, future financing and eventual commercialization of its pipeline.

At June 30, 2026, Trevi held $54.3 million in cash and equivalents and $264.6 million in short-term investments, for approximately $318.9 million of cash and liquid investments. This was up from $171.8 million at March 31, 2026, and $203.9 million at June 30, 2025. Total assets increased to $330.5 million from $179.6 million at the end of the first quarter, primarily reflecting the larger investment balance and financing activity.

The balance sheet is largely unleveraged. Total liabilities were only $9.0 million at the end of the second quarter, including no long-term debt, compared with $7.5 million at March 31, 2026. This produced a current ratio of roughly 37 times and gives Trevi substantial near-term financial flexibility. However, the company’s retained earnings deficit reached $360.8 million, reflecting years of accumulated losses.

Operating performance continued to weaken. Second-quarter operating expenses rose to $20.5 million from $14.9 million in the first quarter and $13.7 million in the year-ago quarter. Research and development expense increased to $15.2 million, while selling, general and administrative expense rose to $5.4 million. Net loss widened to $17.8 million, or $0.11 per share, compared with a $13.2 million loss, or $0.09 per share, in the first quarter and a $12.3 million loss, or $0.09 per share, in the second quarter of 2025.

Investment income provided a partial offset. Interest and investment income increased to $2.7 million in the second quarter from $1.7 million in the first quarter and $1.4 million in the year-ago period. Even so, this income covered only a portion of the company’s operating expenses, and Trevi has not yet generated product revenue.

Cash usage also remains significant. Net cash used in operating activities was $17.4 million in the second quarter, compared with $16.7 million in the first quarter and $10.1 million in the second quarter of 2025. The increase is consistent with higher research and development spending. Trevi reported a $32.7 million increase in cash during the quarter, but that improvement was driven primarily by $164.4 million of financing cash flow, rather than by operations.

  • Strong liquidity: Cash and short-term investments totaled approximately $318.9 million at June 30, 2026, providing a sizable funding base for clinical development.
  • Minimal leverage: Trevi had no long-term debt and total liabilities of only $9.0 million, limiting interest-rate and refinancing risk.
  • Higher investment income: Interest and investment income rose to $2.7 million in Q2 2026, helping offset part of the operating loss.
  • Financing access: Financing activity added $164.4 million of cash in Q2 2026, and common stock on the balance sheet increased substantially, indicating continued access to equity capital.
  • Large liquid-asset portfolio: Short-term investments represented most of Trevi’s liquidity. This supports capital preservation and interest income, but the balance may fluctuate as investments are purchased, sold or used to fund operations.
  • Clinical-stage financial profile: The company has reported no revenue in the presented periods, so valuation and financial performance remain tied primarily to pipeline milestones rather than current sales.
  • Persistent operating losses: Trevi has reported recurring quarterly net losses across the presented four-year period, with a $17.8 million loss in Q2 2026.
  • Accelerating expenses: Quarterly operating expenses increased to $20.5 million in Q2 2026 from $10.2 million in Q4 2025 and $13.7 million in Q2 2025, led by higher research and development spending.
  • Heavy cash burn: Operating cash outflow was $17.4 million in Q2 2026, and the company has consistently consumed cash from operations. Continued spending could reduce liquidity if financing slows.
  • Shareholder dilution: Weighted-average basic shares outstanding increased to 156.6 million in Q2 2026 from 145.6 million in Q1 and 130.4 million in Q2 2025, indicating that equity financing has increased the share count.

Overall, Trevi’s balance sheet is considerably stronger than its income statement. The company appears well funded in the near term and carries little debt, but it remains dependent on capital markets because revenue is absent and operating cash burn is increasing. Investors should focus on clinical execution, the pace of R&D spending, future equity issuance and the company’s ability to convert its cash resources into a commercially viable product.

09/20/26 07:31 PM ETAI Generated. May Contain Errors.

Trevi Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Trevi Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Trevi Therapeutics' net income appears to be on an upward trend, with a most recent value of -$42.76 million in 2025, rising from -$20.55 million in 2018. The previous period was -$47.91 million in 2024. View Trevi Therapeutics' forecast to see where analysts expect Trevi Therapeutics to go next.

Trevi Therapeutics' total operating income in 2025 was -$49.33 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $49.33 million

Over the last 7 years, Trevi Therapeutics' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

Trevi Therapeutics' total liabilities were at $10.20 million at the end of 2025, a 9.4% decrease from 2024, and a 138.3% increase since 2018.

In the past 7 years, Trevi Therapeutics' cash and equivalents has ranged from $7.20 million in 2018 to $57.31 million in 2019, and is currently $18.91 million as of their latest financial filing in 2025.

Over the last 7 years, Trevi Therapeutics' book value per share changed from -250.21 in 2018 to 1.43 in 2025, a change of -100.6%.


Related Companies

Financial statements for NASDAQ:TRVI last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
No Wallstreet. No Advisor. No Problem.
Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...
Awesomely | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel